S63845 was the first MCL-1 inhibitor reported to be effective in tumor models, binding human Mcl-1 at a Kd of 0.19 nM, and was shown to have broad therapeutic applicability in multiple myeloma, lymphoma, leukemia, and primary AML cell groups [46]. This evidence concerns the gene MCL1 and neoplasm.